{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:25:24Z","timestamp":1787217924128,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.ajkd.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:08:23Z","timestamp":1782850103000},"page":"492-497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemophagocytic Lymphohistiocytosis and Fibroblast Growth Factor 23 (FGF23)\u2013Induced Hypophosphatemia"],"prefix":"10.1053","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-1362","authenticated-orcid":false,"given":"Martina","family":"Cacciapuoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan Z.","family":"Bahrainwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Abra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2026.04.013_bib1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/bjh.19773","article-title":"Incorrigible inflammation","volume":"205","author":"Ariffin","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ajkd.2026.04.013_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"key":"10.1053\/j.ajkd.2026.04.013_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2026.04.013_bib4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1158\/2326-6066.CIR-22-0418","article-title":"Hypophosphatemia due to increased effector cell metabolic activity is associated with neurotoxicity symptoms in CD19-targeted CAR T-cell therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1053\/j.ajkd.2026.04.013_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.18504","article-title":"Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy","volume":"200","author":"Nakamura","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ajkd.2026.04.013_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41409-023-02083-4","article-title":"Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy","volume":"58","author":"Barker","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.ajkd.2026.04.013_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.ajkd.2023.04.017","article-title":"Calcium and phosphate disorders: core curriculum 2024","volume":"83","author":"Murray","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2026.04.013_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2026.04.013_bib9","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/ndt\/gfab331","article-title":"Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine","volume":"37","author":"Derain Dubourg","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2026.04.013_bib11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.20945\/2359-3997000000555","article-title":"New treatments for rare bone diseases: hypophosphatemic rickets\/osteomalacia","volume":"66","author":"Marques","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2026.04.013_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116004","article-title":"Burosumab treatment for fibrous dysplasia","volume":"150","author":"Gladding","year":"2021","journal-title":"Bone"},{"key":"10.1053\/j.ajkd.2026.04.013_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4248\/BR201302002","article-title":"FGF23 and phosphate wasting disorders","volume":"1","author":"Huang","year":"2013","journal-title":"Bone Res"},{"key":"10.1053\/j.ajkd.2026.04.013_bib14","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.ajkd.2026.04.013_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1210\/js.2018-00010","article-title":"Fibroblast growth factor 23\u2013induced hypophosphatemia in acute leukemia","volume":"2","author":"Reinert","year":"2018","journal-title":"J Endocr Soc"},{"key":"10.1053\/j.ajkd.2026.04.013_bib16","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/jbmr.4702","article-title":"Determination of FGF23 Levels for the diagnosis of FGF23-mediated hypophosphatemia","volume":"37","author":"Hartley","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.ajkd.2026.04.013_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2026.04.013_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.117782","article-title":"Prevalence of FGF23 elevation in patients with hypophosphatemia","volume":"554","author":"Oris","year":"2024","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.ajkd.2026.04.013_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-230X-12-44","article-title":"Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease","volume":"12","author":"El-Hodhod","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.ajkd.2026.04.013_bib20","article-title":"Fibroblast growth factor 23 during septic shock and myocardial injury in ICU patients","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"key":"10.1053\/j.ajkd.2026.04.013_bib21","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1158\/2767-9764.CRC-24-0250","article-title":"Hypophosphatemia correction reduces ICANS incidence and duration in CAR T-cell therapy: a pooled clinical trial analysis","volume":"4","author":"Tang","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1053\/j.ajkd.2026.04.013_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-023-00599-1","article-title":"CAR-T cells and the kidney: insights from the WHO safety database","volume":"37","author":"G\u00e9rard","year":"2023","journal-title":"BioDrugs"},{"key":"10.1053\/j.ajkd.2026.04.013_bib23","article-title":"Tumor-induced osteomalacia: a systematic literature review","volume":"21","author":"\u00c1lvarez-Rivas","year":"2024","journal-title":"Bone Rep"},{"key":"10.1053\/j.ajkd.2026.04.013_bib24","doi-asserted-by":"crossref","first-page":"ziae152","DOI":"10.1093\/jbmrpl\/ziae152","article-title":"Unusual PHEX variants implicate uncommon genetic mechanisms for X-linked hypophosphatemic rickets","volume":"9","author":"Alzoebie","year":"2024","journal-title":"JBMR Plus"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:43:07Z","timestamp":1787215387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626009856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0272638626009856"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.04.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophagocytic Lymphohistiocytosis and Fibroblast Growth Factor 23 (FGF23)\u2013Induced Hypophosphatemia","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}